查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物防御市场规模、份额和趋势分析报告：按产品（炭疽、天花、肉毒桿菌、辐射/核）、地区（北美、欧洲、亚太地区）、分部预测，2023-2030 年
市场调查报告书
商品编码
1178739

生物防御市场规模、份额和趋势分析报告：按产品（炭疽、天花、肉毒桿菌、辐射/核）、地区（北美、欧洲、亚太地区）、分部预测，2023-2030 年

Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Region (North America, Europe, APAC), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

生物防御市场增长和趋势

根据 Grand View Research, Inc. 的一份新报告，到 2030 年，全球生物防御市场规模预计将达到 228 亿美元，从 2022 年到 2030 年的复合年增长率为 5.0%。 生物防御可以简洁地定义为为恢復一个国家的生物安全而采取的一套综合措施（识别、规划和准备）。

它旨在解决重大生物威胁和传染病，这些威胁和传染病很容易被用作生物武器来煽动内乱和生物恐怖主义。 生物威胁，无论是自然的、意外的还是故意的，都是各种形式的重大威胁。 积极的政府举措、私营公司增加投资以及各种病毒的传播等因素正在推动市场的增长。

由于过去炭疽、天花和肉毒梭菌等病毒病原体的生物恐怖主义袭击，生物防御已成为一个主要的重点领域。 各国越来越需要取得进展以保护自己免受严重威胁，这仍然是增长的关键驱动力。 2017 年，美国疾病控制与预防中心 (CDC) 表示，它追踪了 190 多个国家的 170 多种地方病和疫情。

据世界卫生组织称，每年约有 6,500,000 人死于与季节性流感相关的呼吸道疾病。 寨卡病毒和埃博拉病毒的反復爆发迫使州政府制定生物防御计划并製定战略。 这些新计划将有助于规划和应对未来的疫情。

2018 年，美国政府宣布了一项国家生物防御战略，以管理生物威胁的风险。 这种新策略可以从源头检测并遏制生物威胁，同时促进生物医学创新并改进应急响应。 预计这些因素将推动市场的增长。

生物防御市场报告要点

到 2022 年，炭疽细分市场将主导市场。 这些生物试剂在环境中的存留时间更长，并且容易释放，因此具有更高的潜在风险

其他部分预计在预测期内的复合年增长率最高。 该部分包括寨卡病毒、埃博拉病毒和马尔堡病毒等潜在威胁。 相关疫情的增加仍然是主要的增长动力。

由于联邦政府提供了大量资金、技术进步和公众意识的提高，预计在预测期内北美将主导全球市场。

内容

第1章调查方法及范围

  • 市场细分和范围
    • 产品
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的详细信息
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析（模型 1）
  • 次要信息列表
  • 主要信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场前景

第 3 章生物防御市场：变量、趋势和范围

  • 市场细分和范围
  • 市场动态
    • 市场驱动因素分析
    • 在美国存在有利的政府举措
      • 2016-2021 年联邦机构生物防御基金
      • 医疗产品紧急使用授权
      • 项目生物防护法
      • 私营企业的投资增加
    • 埃博拉病毒、寨卡病毒和流感等各种病原体的传播
    • 市场製约因素分析
      • 在发展中国家和发展中国家的市场渗透率低
  • 描绘渗透率和增长前景
  • Biodefense：一种市场分析工具
    • 行业分析 - 搬运工
    • PESTEL 分析
  • 生物防御竞争情景，2015 年
    • 生物防御
      • 生物防御：产品管线
    • 化学防御
      • 化学防御：产品管道
    • 核与辐射防护
      • 核与辐射防护：产品管道分析

第 4 章生物防御市场：产品细分分析

  • 生物防御：2022 年和 2030 年市场份额分析
  • 炭疽桿菌
  • 天花
  • 肉毒中毒
  • 辐射/核能
    • 其他
      • 其他生物防御产品市场，2018-2030 年（百万美元）

第 5 章生物防御市场：区域分析

  • 生物防御：区域市场份额分析，2022 年和 2030 年
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多边环境协定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第6章公司简介

  • Xoma 公司
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Altimmune, Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Emergent Biosolutions Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Dynavax 技术公司
    • 公司简介
    • 财务业绩
    • 战略举措
  • Siga Technologies, Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Elusys Therapeutics, Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Ichor 医疗系统
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Dynport 疫苗有限公司
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 克利夫兰生物实验室
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 巴伐利亚北欧人
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Ology Bioservices
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Alnylam Pharmaceuticals, Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
Product Code: 978-1-68038-313-3

Biodefense Market Growth & Trends:

The global biodefense market size is expected to reach USD 22.8 billion by 2030, and it is set to expand at 5.0% CAGR from 2022 to 2030, according to a new report by Grand View Research, Inc. Biodefense can be briefly defined as a set of comprehensive measures (identification, planning, and preparedness) undertaken to restore the biosecurity of a country.

It aims to tackle key biological threats or infectious diseases that can be easily used as a bioweapon to instigate social unrest and bioterrorism. Biological threats can be natural, accidental, or deliberate in origin and in all forms, present a grave threat. Factors like the presence of favorable government initiatives, increasing investment by private players, and the growing prevalence of various viral agents are fueling market growth.

Previous incidents of bioterrorism caused by viral agents like anthrax, smallpox, and botulism have made Biodefense a major focus area. The increased need for advancements for countries to defend themselves against grave threats remains the primary driver of growth. In 2017, the Centers for Disease Control and Prevention (CDC) stated that they had tracked more than 170 unique diseases, and outbreaks in more than 190 countries.

According to WHO, around 6,50,000 people die of respiratory diseases associated with seasonal flu annually. Repeated outbreaks of Zika and Ebola virus have coerced state governments to construct and strategize biodefense programs. These new programs will assist in planning and response during future outbreaks.

In 2018, the U.S. government announced a national biodefense strategy to manage the risk of biological threats. The new strategy can detect and contain bio-threats at its source, while simultaneously promoting biomedical innovation, and improving emergency response. These factors are expected to boost market growth.

Biodefense Market Report Highlights:

  • The anthrax segment dominated the market in 2022. These bioagents can last longer in the environment, and are released with ease, posing a high potential risk
  • The other segment is expected to register the highest CAGR during the forecast period. This segment includes potential threats such as zika, Ebola, and Marburg's virus. The rising incidents of related outbreaks remain the key growth driver
  • North America is expected to dominate the global market during the forecast period, owing to the presence of high federal funding, technological advancements, and growing awareness among the population

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1
    • 1.10.2 Objective - 2
    • 1.10.3 Objective - 3
    • 1.10.4 Objective - 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Biodefence Market: Variables, Trends, & Scope

  • 3.1 Market Segmentation And Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Presence Of Favorable Government Initiatives In The U.S.
      • 3.2.2.1 Biodefense Funding In Fy 2016 - 2021 By Federal Agency
      • 3.2.2.2 Emergency Use Authorization Of Medical Products
      • 3.2.2.3 Project Bioshield Act
      • 3.2.2.4 Growing Investment From Private Players
    • 3.2.3 Growing Prevalence Of Various Agents Such As Ebola Virus, Zika Virus, Flu, And Others
    • 3.2.4 Market Restraint Analysis
      • 3.2.4.1 Low Market Penetration In Developing And Underdeveloped Countries
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Biodefence: Market Analysis Tools
    • 3.4.1 Industry Analysis - Porter's
    • 3.4.2 Pestel Analysis
  • 3.5 Biodefense Competitive Scenario, 2015
    • 3.5.1 Biological Defense
      • 3.5.1.1 Biological Defense: Product Pipeline
    • 3.5.2 Chemical Defense
      • 3.5.2.1 Chemical Defense: Product Pipeline
    • 3.5.3 Nuclear/Radiological Defense
      • 3.5.3.1 Nuclear/Radiological Defense: Product Pipeline Analysis

Chapter 4 Biodefence Market: Product Segment Analysis

  • 4.1 Biodefence: Agent Market Share Analysis, 2022 & 2030
  • 4.2 Anthrax
    • 4.2.1 Biodefense Against Anthrax Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.3 Smallpox
    • 4.3.1 Biodefense Against Smallpox Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.4 Botulism
    • 4.4.1 Biodefense Against Botulism Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.5 Radiation/Nuclear
    • 4.5.1 Biodefense Against Radiation/Nuclear Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2 Others
      • 4.5.2.1 Other Biodefense Products Market, 2018 - 2030 (USD Million)

Chapter 5 Biodefence Market: Regional Analysis

  • 5.1 Biodefence: Regional Market Share Analysis, 2022 & 2030
  • 5.2 North America
    • 5.2.1 North America Biodefence Market, 2018 - 2030 (USD Million)
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. Biodefence Market, 2018 - 2030 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada Biodefence Market, 2018 - 2030 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.2 U.K.
      • 5.3.2.1 U.K. Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Germany Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.4 France
      • 5.3.4.1 France Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.5 Italy
      • 5.3.5.1 Italy Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.6 Spain
      • 5.3.6.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.7 Denmark
      • 5.3.7.1 Denmark Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.8 Sweden
      • 5.3.8.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
    • 5.3.9 Norway
      • 5.3.9.1 Norway Biodefence Market, 2018 - 2030 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.2 China
      • 5.4.2.1 China Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.3 India
      • 5.4.3.1 India Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.4 Japan
      • 5.4.4.1 Japan Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.5 Australia
      • 5.4.5.1 Australia Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.6 Thailand
      • 5.4.6.1 Thailand Biodefence Market, 2018 - 2030 (USD Million)
    • 5.4.7 South Korea
      • 5.4.7.1 South Korea Biodefence Market, 2018 - 2030 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America Biodefence Market, 2018 - 2030 (USD Million)
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil Biodefence Market, 2018 - 2030 (USD Million)
    • 5.5.3 Mexico
      • 5.5.3.1 Mexico Biodefence Market, 2018 - 2030 (USD Million)
    • 5.5.4 Argentina
      • 5.5.4.1 Argentina Biodefence Market, 2018 - 2030 (USD Million)
  • 5.6 MEA
    • 5.6.1 MEA Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.3 Saudi Arabia
      • 5.6.3.1 Saudi Arabia Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.4 UAE
      • 5.6.4.1 UAE Biodefence Market, 2018 - 2030 (USD Million)
    • 5.6.5 Kuwait
      • 5.6.5.1 Kuwait Biodefence Market, 2018 - 2030 (USD Million)

Chapter 6 Company Profiles

    • 6.1.1 Xoma Corporation
      • 6.1.1.1 Company Overview
      • 6.1.1.2 Financial Performance
      • 6.1.1.3 Product Benchmarking
      • 6.1.1.4 Strategic Initiatives
    • 6.1.2 Altimmune, Inc.
      • 6.1.2.1 Company Overview
      • 6.1.2.2 Financial Performance
      • 6.1.2.3 Product Benchmarking
      • 6.1.2.4 Strategic Initiatives
    • 6.1.3 Emergent Biosolutions Inc.
      • 6.1.3.1 Company Overview
      • 6.1.3.2 Financial Performance
      • 6.1.3.3 Product Benchmarking
      • 6.1.3.4 Strategic Initiatives
    • 6.1.4 Dynavax Technologies Corporation
      • 6.1.4.1 Company Overview
      • 6.1.4.2 Financial Performance
      • 6.1.4.3 Strategic Initiatives
    • 6.1.5 Siga Technologies, Inc.
      • 6.1.5.1 Company Overview
      • 6.1.5.2 Financial Performance
      • 6.1.5.3 Product Benchmarking
      • 6.1.5.4 Strategic Initiatives
    • 6.1.6 Elusys Therapeutics, Inc.
      • 6.1.6.1 Company Overview
      • 6.1.6.2 Financial Performance
      • 6.1.6.3 Product Benchmarking
      • 6.1.6.4 Strategic Initiatives
    • 6.1.7 Ichor Medical Systems
      • 6.1.7.1 Company Overview
      • 6.1.7.2 Financial Performance
      • 6.1.7.3 Product Benchmarking
      • 6.1.7.4 Strategic Initiatives
    • 6.1.8 Dynport Vaccine Company Llc
      • 6.1.8.1 Company Overview
      • 6.1.8.2 Financial Performance
      • 6.1.8.3 Product Benchmarking
      • 6.1.8.4 Strategic Initiatives
    • 6.1.9 Cleveland Biolabs
      • 6.1.9.1 Company Overview
      • 6.1.9.2 Financial Performance
      • 6.1.9.3 Product Benchmarking
      • 6.1.9.4 Strategic Initiatives
    • 6.1.10 Bavarian Nordic
      • 6.1.10.1 Company Overview
      • 6.1.10.2 Financial Performance
      • 6.1.10.3 Product Benchmarking
      • 6.1.10.4 Strategic Initiatives
    • 6.1.11 Ology Bioservices
      • 6.1.11.1 Company Overview
      • 6.1.11.2 Financial Performance
      • 6.1.11.3 Product Benchmarking
      • 6.1.11.4 Strategic Initiatives
    • 6.1.12 Alnylam Pharmaceuticals, Inc.
      • 6.1.12.1 Company Overview
      • 6.1.12.2 Financial Performance
      • 6.1.12.3 Product Benchmarking
      • 6.1.12.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. government civilian biodefense funding, by agencies for the years 2017 - 2019 in USD Million.
  • Table 4 National Institutes of Health Funding for the years 2017 - 2019 in USD Million
  • Table 5 Travel Associated cases of Zika Virus in the U.S in 2019
  • Table 6 Ebola Funding to WHO, 2019

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Biodefence market snapshot (2022)
  • Fig. 10 Biodefence market segmentation
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 16 Biodefence market product type outlook: Segment dashboard
  • Fig. 17 Biodefence market: Product movement analysis
  • Fig. 18 Anthrax market, 2018 - 2030 (USD Million)
  • Fig. 19 Smallpox market, 2018 - 2030 (USD Million)
  • Fig. 20 Botulism market, 2018 - 2030 (USD Million)
  • Fig. 21 Radiation and Nuclear market, 2018 - 2030 (USD Million)
  • Fig. 22 Others market, 2018 - 2030 (USD Million)
  • Fig. 23 Regional market: Key takeaways
  • Fig. 24 Regional outlook, 2022 & 2030
  • Fig. 25 North America market, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 27 Canada market, 2018 - 2030 (USD Million)
  • Fig. 28 Europe market, 2018 - 2030 (USD Million)
  • Fig. 29 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 30 Germany market, 2018 - 2030 (USD Million)
  • Fig. 31 France market, 2018 - 2030 (USD Million)
  • Fig. 32 Italy market, 2018 - 2030 (USD Million)
  • Fig. 33 Spain market, 2018 - 2030 (USD Million)
  • Fig. 34 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 35 China market, 2018 - 2030 (USD Million)
  • Fig. 36 India market, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market, 2018 - 2030 (USD Million)
  • Fig. 38 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 39 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 41 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 42 MEA market, 2018 - 2030 (USD Million)
  • Fig. 43 South Africa market, 2018 - 2030 (USD Million)